Growth hormone therapy can help reverse growth problems in children with kidney failure, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology. However, the researchers noted that treatment increases bone turnover and interrupts the relationship between bone turnover and a blood marker of bone health, making it difficult for doctors to assess patients' bone health by blood tests alone.
Abnormally high or abnormally low bone turnover can increase the severity of growth retardation in children with kidney disease, so finding a normal balance is important. Recombinant human growth hormone can often help, but response is variable in children on dialysis, the researchers said.
To evaluate the direct effect of recombinant human growth hormone therapy on the skeleton in pediatric patients, Justine Bacchetta, MD, PhD, Katherine Wesseling-Perry, MD, and colleagues from the David Geffen School of Medicine at UCLA randomized 33 pediatric dialysis patients to therapy with or without growth hormone.
- Among the major findings:
- Growth hormone therapy resulted in greater increases in height.
- Growth hormone enhanced bone turnover in patients with baseline low bone turnover, but it counteracted the bone-turnover lowering effects of vitamin D therapy in patients with high bone turnover.
- Parathyroid hormone values were similar in patients who received growth hormone compared with those who did not, despite marked differences in final rates of bone formation.
The findings suggest that growth hormone may help treat poor growth and low bone turnover in children on dialysis. It may also improve growth in children with high bone turnover, but it may not benefit their overall bone health.